Latest Alzheimer Society of Canada Stories
PHOENIX, May 21 /PRNewswire/ -- The Alzheimer's Association released a report on Wednesday, May 19, predicting that the cost of Alzheimer's disease over the next 40 years would reach $20 trillion if newer treatments are not on the horizon. "Today, there are no treatments that can prevent, delay, slow or stop the progression of Alzheimer's disease," noted Harry Johns, President and CEO of the Alzheimer's Association.
PHOENIX, May 20 /PRNewswire/ -- The largest gathering of Alzheimer's disease researchers, medical experts, caregivers and policy makers in Arizona's history will gather Friday, May 21 to continue the urgent battle against the disease that today has more than 78,000 victims in Arizona alone. About 1,200 people are expected to attend the 12th Annual Conference of the Arizona Alzheimer's Consortium.
Internationally Recognized Researcher to Present on May 22 CONCORD, N.H., April 22 /PRNewswire-USNewswire/ -- Alzheimer's disease can be devastating to families who become caregivers.
WASHINGTON, March 9 /PRNewswire-USNewswire/ -- According to the Alzheimer's Association'sÂ® 2010 Alzheimer's Disease Facts and Figures, African-Americans are about two times more likely and Hispanics are about one and one-half times more likely than their white counterparts to have Alzheimer's and other dementias.
LONDON, March 4, 2010 /PRNewswire/ -- Beneficial Alzheimer's therapies that don't use drugs, and an update on prevention efforts, are the focus of the second day's plenary sessions at the 25th International Conference of Alzheimer's Disease International (ADI), March 12, 2010 at the Grand Hotel Palace, Thessaloniki, Greece. Prof.
LONDON, March 4, 2010 /PRNewswire/ -- "What's new" in Alzheimer's disease medical treatments and diagnosis is the focus of the first day's plenary sessions at the 25th International Conference of Alzheimer's Disease International (ADI), March 11, 2010 at the Grand Hotel Palace, Thessaloniki, Greece. Sam Gandy, M.D., Ph.D.
Alzheimer's Association Statement CHICAGO, March 3 /PRNewswire-USNewswire/ -- "The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer.
Alzheimer's Association Statement WASHINGTON, Feb.
The benefits of marijuana in tempering or reversing the effects of Alzheimer's disease have been challenged in a new study by researchers at the University of British Columbia and Vancouver Coastal Health Research Institute.
NORTH CHICAGO, Ill., Nov. 13 /PRNewswire-USNewswire/ -- Research that is targeting the early diagnosis of Alzheimer disease has drawn national attention to the work of Michael Seidenberg, PhD, a faculty member at Rosalind Franklin University of Medicine and Science. Dr.
- In medieval musical notation, a sign or neume denoting a shake or trill.